FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308133027> ?p ?o ?g. }

• W4308133027 endingPage "A173" @default.
• W4308133027 startingPage "A173" @default.
• W4308133027 abstract "Abstract Bisphosphonates are the first-line treatment for several bone and mineral disorders. Randomized trials and cohort studies have reported increased rates of atrial fibrillation in patients receiving bisphosphonates, however, uncertainty remains as to whether other electrical disturbances are precipitated by bisphosphonates. We aimed to review the literature for studies reporting ECG findings in patients receiving intravenous bisphosphonates for any indication. We searched MEDLINE and EMBASE on 06/01/2022 for studies reporting ECG parameters following administration of intravenous bisphosphonates. We excluded studies that only reported atrial fibrillation, case reports and animal or cell-based studies. Study quality was assessed using the Newcastle-Ottawa Scale. Continuous data were meta-analysed if reported in at least two studies. Random-effects models were fitted and reported as standardized mean difference (SMD) with 95% confidence intervals (95%CI). Heterogeneity was determined by the I 2 statistic. All data were computed using R (4.1.1). We found 1,123 records of which six met our inclusion and exclusion criteria, of which five had data for meta-analysis. Studies were of low to moderate quality. Five studies used zoledronic acid while one study used pamidronate. Most studies [n=4] were conducted in postmenopausal women with osteoporosis, one study was conducted in patients with bone metastases and one study was conducted in children with cerebral palsy and osteoporosis. Most studies [n=4] reported outcomes in the sub-acute (&gt;24 hours) phase. Study populations ranged from n=15 to n=116. There was a significant difference in QTc dispersion (SMD= -0.456 milliseconds [95%CI: -0.800 to -0.113]; I 2 = 0%; n= 67 patients; k= 2 studies) but no differences in heart rate, P wave (maximum), P wave (minimum), P wave dispersion, PR interval, QRS duration, QTc (maximum), QTc (minimum), or QTc. The correlation between pre- and post-infusion QTc dispersion was rho= 0.981 (p=0.866). Results were unchanged when analysing studies reporting acute or sub-acute phase ECG changes. Overall, there is insufficient and low quality evidence to support an association between intravenous bisphosphonate administration and acute phase dysrhythmias. These data underscore the importance of performing a pre-infusion ECG to evaluate potentially unreported conduction abnormalities. Presentation: No date and time listed" @default.
• W4308133027 created "2022-11-08" @default.
• W4308133027 creator A5003433351 @default.
• W4308133027 creator A5042414719 @default.
• W4308133027 date "2022-11-01" @default.
• W4308133027 modified "2023-10-14" @default.
• W4308133027 title "ODP112 Post-infusion ECG Changes in Patients Receiving Intravenous Bisphosphonates: a Systematic Review and Meta-Analysis" @default.
• W4308133027 doi "https://doi.org/10.1210/jendso/bvac150.355" @default.
• W4308133027 hasPublicationYear "2022" @default.
• W4308133027 type Work @default.
• W4308133027 citedByCount "0" @default.
• W4308133027 crossrefType "journal-article" @default.
• W4308133027 hasAuthorship W4308133027A5003433351 @default.
• W4308133027 hasAuthorship W4308133027A5042414719 @default.
• W4308133027 hasBestOaLocation W43081330271 @default.
• W4308133027 hasConcept C119423318 @default.
• W4308133027 hasConcept C126322002 @default.
• W4308133027 hasConcept C142724271 @default.
• W4308133027 hasConcept C168563851 @default.
• W4308133027 hasConcept C201903717 @default.
• W4308133027 hasConcept C204787440 @default.
• W4308133027 hasConcept C2776326535 @default.
• W4308133027 hasConcept C2776541429 @default.
• W4308133027 hasConcept C2777596629 @default.
• W4308133027 hasConcept C2779161974 @default.
• W4308133027 hasConcept C28804328 @default.
• W4308133027 hasConcept C44249647 @default.
• W4308133027 hasConcept C71924100 @default.
• W4308133027 hasConcept C95190672 @default.
• W4308133027 hasConceptScore W4308133027C119423318 @default.
• W4308133027 hasConceptScore W4308133027C126322002 @default.
• W4308133027 hasConceptScore W4308133027C142724271 @default.
• W4308133027 hasConceptScore W4308133027C168563851 @default.
• W4308133027 hasConceptScore W4308133027C201903717 @default.
• W4308133027 hasConceptScore W4308133027C204787440 @default.
• W4308133027 hasConceptScore W4308133027C2776326535 @default.
• W4308133027 hasConceptScore W4308133027C2776541429 @default.
• W4308133027 hasConceptScore W4308133027C2777596629 @default.
• W4308133027 hasConceptScore W4308133027C2779161974 @default.
• W4308133027 hasConceptScore W4308133027C28804328 @default.
• W4308133027 hasConceptScore W4308133027C44249647 @default.
• W4308133027 hasConceptScore W4308133027C71924100 @default.
• W4308133027 hasConceptScore W4308133027C95190672 @default.
• W4308133027 hasIssue "Supplement_1" @default.
• W4308133027 hasLocation W43081330271 @default.
• W4308133027 hasLocation W43081330272 @default.
• W4308133027 hasOpenAccess W4308133027 @default.
• W4308133027 hasPrimaryLocation W43081330271 @default.
• W4308133027 hasRelatedWork W2027294898 @default.
• W4308133027 hasRelatedWork W2029532220 @default.
• W4308133027 hasRelatedWork W2094000083 @default.
• W4308133027 hasRelatedWork W2333943198 @default.
• W4308133027 hasRelatedWork W2727433614 @default.
• W4308133027 hasRelatedWork W2748167152 @default.
• W4308133027 hasRelatedWork W2762279224 @default.
• W4308133027 hasRelatedWork W3036326648 @default.
• W4308133027 hasRelatedWork W3151722194 @default.
• W4308133027 hasRelatedWork W3211375105 @default.
• W4308133027 hasVolume "6" @default.
• W4308133027 isParatext "false" @default.
• W4308133027 isRetracted "false" @default.
• W4308133027 workType "article" @default.